ClinicalTrials.gg

Program

enozertinib

Also written as “ORIC-114”, “ORIC-114 Dose 1 + amivantamab” and “ORIC-114 Dose 2 + amivantamab”.

Its studies are mostly in Breast Neoplasms, led by ORIC Pharmaceuticals.

Furthest: phase 2, since Mar 24, 20223 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ORIC Pharmaceuticals32 open or runningphase 2since Mar 24, 2022Mar 24, 2022Dec 2026phase 1 · NCT06816992

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2022First study: phase 2 study in Breast NeoplasmsFirst studyNCT05315700 · 350 planned · United States, Australia, Canada and more
  2. Aug 17, 2023Phase 1 study in Food Effect in Healthy ParticipantsNCT06012721 · 32 enrolled · Australia
  3. Feb 3, 2025Phase 1 study in Solid TumorsNCT06816992 · 76 planned · United States, Australia, Canada

Ahead

  1. Dec 2026Primary completion: phase 1 study in Solid TumorsNCT06816992
  2. Jun 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05315700

TargetBeta

EGFR →ERBB2 →read by rule
“An orally bioavailable, central nervous system (CNS) penetrating, mutant-selective covalent inhibitor of epidermal growth factor receptor (EGFR; ErbB1) and human epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2) alterations, including exon 20 insertion (Ex20ins) mutations, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
sunvozertinibruleDizal Pharmaceuticalsphase 312
sevabertinibruleBayerphase 38
EGFR/HER2 Mutant-selective Inhibitor BH-30643ruleblossomhill-therapeuticsphase 21
GENSCI139ruleChangchun GeneScience Pharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06816992Solid Tumors · United States, Australia, Canada1RecruitingDec 202676
NCT06012721Food Effect in Healthy Participants · Australia1CompletedNov 23, 202332
NCT05315700Breast Neoplasms · United States, Australia, Canada and more2RecruitingJun 2027350

How it is read

Names in the registry

  • “ORIC-114”, 2 entries
  • “ORIC-114 Dose 1 + amivantamab”, 1 entry
  • “ORIC-114 Dose 2 + amivantamab”, 1 entry
  • “ORIC-114 Dose 3 + amivantamab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.